What happened
Researchers built a machine learning system that uses graph-based neural networks to predict whether a given small-molecule drug will inhibit cancer cell growth in specific cell types, achieving 87% accuracy on test data. This matters because cancer drug discovery currently relies heavily on expensive lab screening across dozens of cell lines; a reliable computational predictor could reduce that workload, speed up which candidates get tested next, and help match drugs to tumor types earlier.
Why it matters
Drug response prediction in cancer has been a slow, expensive bottleneck because tumor cells vary so much — the same drug works in one cell line and fails in another. If this model's accuracy holds in real lab validation, it could shift early-stage drug screening from purely experimental to mostly computational, cutting both cost and time before human trials.